Product Information
BENICAR HCT 40-25 MG TABLET is a brand product labeled by Cosette Pharmaceuticals, Inc., priced at $15.6513 per EA under NDC 00713086530. Its NADAC has been published 184 times since Jan 18, 2023.
FDA first approved this application on Jun 5, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 40 mg/1; mg/1
Manufacturer
Cosette Pharmaceuticals, Inc.NDC
00713086530
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
7/22/2026
Active Ingredients
HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
New Drug (NDA)
FDA Application
NDA021532FDA Approved
6/5/2003
TE Code
AB
On Market Since
9/1/2022
Pharmacological Classes
Price Statistics
The NADAC for BENICAR HCT 40-25 MG TABLET has been published 184 times since Jan 18, 2023, and over the history we have for it it has risen 31.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $15.6513 per EA |
|---|---|
| All-time high | $15.7729 (Mar 11, 2026) |
| All-time low | $11.8660 (Jan 18, 2023) |
| 52-week high | $15.7729 |
| 52-week low | $15.6513 |
| Median price | $14.1941 |
| Average price | $13.7922 |
| Largest weekly change | +10.0% (Sep 25, 2024) |
| Weeks tracked | 184 |
| Tracking since | Jan 18, 2023 |
1W
N/A
1M
N/A
3M
0.0%
6M
-0.4%
1Y
-0.1%
3Y
+20.0%
5Y
N/A
All
+31.9%
Last surveyed Jul 22, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olmesartan medoxomil-hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cosette Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olmesartan medoxomil-hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BENICAR HCT 40-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BENICAR HCT 40-25 MG TABLET, manufactured by Cosette Pharmaceuticals, Inc., is $15.6513 per EA (NDC 00713086530), effective Jul 22, 2026.
How has the price of BENICAR HCT 40-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for BENICAR HCT 40-25 MG TABLET has risen 31.9%. It has been tracked across 184 weekly CMS publications since Jan 18, 2023.
What are the highest and lowest recorded NADAC prices for BENICAR HCT 40-25 MG TABLET?
Since Jan 18, 2023, the NADAC for BENICAR HCT 40-25 MG TABLET has ranged from a low of $11.8660 (Jan 18, 2023) to a high of $15.7729 (Mar 11, 2026), with a median of $14.1941 per EA.
Are there cheaper alternatives to BENICAR HCT 40-25 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of BENICAR HCT 40-25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BENICAR HCT 40-25 MG TABLET?
BENICAR HCT 40-25 MG TABLET (NDC 00713086530) is labeled by Cosette Pharmaceuticals, Inc., and CMS classifies it as a brand product.